کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2999662 | 1180298 | 2009 | 16 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
EFsmSMARTHDMPCLIMPVTTPIMIDSMMNCRMPTISSMGUSCCTVGPRORRTRMDEXHigh-dose melphalanPFs - PF هاScT - ScT درprogression-free survival - بقا بدون پیشرفتEvent-free survival - بقاء بدون وقفهoverall survival - بقای کلThalidomide - تالیدومیدThal - تلهImmunomodulatory drug - داروهای ضد انعقادDexamethasone - دگزامتازونTime to progression - زمان به پیشرفتInternational Staging System - سیستم بین المللی استقرارplasma cell labeling index - شاخص نشانه گذاری سلول های پلاسماConventional chemotherapy - شیمیدرمانی معمولیfluorescence in situ hybridization - فلورسانس در هیبریداسیون در محلFish - ماهیTreatment-related mortality - مرگ و میر مرتبط با درمانMultiple myeloma - مولتیپل میلوماoverall response rate - نرخ پاسخ کلیPartial response - پاسخ جزئیcomplete response - پاسخ کاملStem cell transplant - پیوند سلول های بنیادیVAD - چهmonoclonal gammopathy of undetermined significance - گاموپاتی مونوکلونال از اهمیت نامشخص
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people each year and is the second most common hematologic malignancy. It is part of a spectrum of monoclonal plasma cell disorders, many of which do not require active therapy. During the past decade, considerable progress has been made in our understanding of the disease process and factors that influence outcome, along with development of new drugs that are highly effective in controlling the disease and prolonging survival without compromising quality of life. Identification of well-defined and reproducible prognostic factors and introduction of new therapies with unique modes of action and impact on disease outcome have for the first time opened up the opportunity to develop risk-adapted strategies for managing this disease. Although these risk-adapted strategies have not been prospectively validated, enough evidence can be gathered from existing randomized trials, subgroup analyses, and retrospective studies to develop a working framework. This set of recommendations represents such an effort-the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Mayo Clinic Proceedings - Volume 84, Issue 12, December 2009, Pages 1095-1110
Journal: Mayo Clinic Proceedings - Volume 84, Issue 12, December 2009, Pages 1095-1110
نویسندگان
Shaji K. MD, Joseph R. MD, Francis K. MD, David MD, PhD, Angela MD, Rafael MD, Morie A. MD, Philip R. MD, Suzanne R. MD, Robert A. MD, Martha Q. MD, John A. MD, PhD, Craig B. MD, Vivek MD, Stephen J. MD, PhD, Kristen E. Detweiler RN, CNP, A. Keith MD,